查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553530

iPS 细胞（诱导性多功能干细胞）市场规模、份额和趋势分析报告：按细胞来源类型、应用、最终用途、地区和细分市场预测，2024-2030 年

Induced Pluripotent Stem Cells Market Size, Share & Trends Analysis Report By Derived Cell Type (Hepatocytes, Fibroblasts), By Application (Drug Development), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

iPS细胞（诱导性多功能干细胞）市场成长与趋势：

根据Grand View Research, Inc.最新报告显示，到2030年，全球iPS细胞（诱导性多功能干细胞）市场规模将达到33.1亿美元，2024年至2030年复合年增长率为10.21%，预计将持续成长。

iPS 细胞（诱导性多功能干细胞）（iPSC）市场正在迅速扩大。 iPS细胞（诱导性多功能干细胞）主要用于产生身体必需的所有细胞和组织，以对抗白血病、脊髓损伤、心血管疾病和糖尿病等疾病。

推动市场扩张的其他因素包括研究支出的增加、基因组学倡议的增加以及基因组工程在个人化治疗中应用的快速成长。因此，iPSC 的采用加速，导致市场收益成长。例如，2020 年 10 月，Axxam SpA 和 FUJIFILM Cellular Dynamics, Inc. 宣布建立策略伙伴关係，以推进药物发现过程。透过使用能够实现标靶评估、高通量筛检(HTS) 和高内涵筛检的尖端药物发现技术，这项合作伙伴关係将为药物发现研究人员和科学家提供基于 hiPSC 检测的整合平台。

近年来，医疗保健发展和研究的趋势显着扩大，预计这一趋势将对预测期内对 iPS 细胞（诱导性多功能干细胞）的需求产生重大影响。扩大人类iPSC细胞株在精准医疗中的应用范围以及日益重视干细胞治疗应用预计将成为推动iPS细胞（诱导性多功能干细胞）市场扩张的重要因素。例如，根据两家公司的联合声明，2021 年 3 月，Sana Biotechnology 获得批准使用FUJIFILM Cellular Dynamics 的 iPSC 平台来创建商业性化细胞疗法。细胞疗法可以改善、修改或取代人类生物学，包括细胞、组织和器官。

COVID-19 大流行期间研究活动的活性化也促进了 iPSC 的研究。此外，科学家们不断努力发现新的治疗方法和治疗方法来控制 SARS CoV-2 感染，这增加了对 iPSC 作为研究工具的需求。此外，iPS 细胞（诱导性多功能干细胞）可用于研究人类病毒感染的病理学，因为它们可以产生生理上等效的类器官和器官模型。因此，它支撑着产业的发展。

此外，随着专注于与 iPS 细胞相关的各种科学活动的行业的发展，政府和商业部门正在增加资金，公众对干细胞的认识也透过各种组织不断提高。然而，细胞重编程成本高、伦理问题、流程耗时等挑战在一定程度上阻碍了iPS细胞（诱导性多功能干细胞）产业的发展。此外，低效率、潜在的肿瘤风险和糟糕的编程也是限制 iPSC 市场扩张的问题。

iPS细胞（诱导性多功能干细胞）市场报告亮点

  • 以细胞来源类型来看，纤维母细胞部分占比重最大，2023年为30.51%。医疗保健专业人员越来越偏好将成纤维母细胞作为皮肤问题的潜在治疗方法，这正在推动该领域的发展。
  • 按应用来看，药物研发领域占比最大，2023年为49.03%。慢性病的流行、久坐的生活方式等增加了对个人化治疗的需求，而製药和生物技术公司对利用 iPS 细胞开发药物的兴趣日益浓厚，正在推动该行业的成长。
  • 按最终用途划分，製药和生物技术公司占最大份额，2023年为59.83%。该细分市场预计将主导市场，因为它使用 iPS 细胞（诱导性多功能干细胞）製造和开发针对各种疾病的各种干细胞产品和技术。
  • 2023年，北美将占据36.11%的较大份额。这主要是由于创新系统和技术在药物研究、毒性测试和疾病建模中的使用越来越多，其中干细胞疗法在该地区获得接受是推动市场的主要原因。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章 iPS Cell（诱导性多功能干细胞）市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场推动要素分析
    • 市场限制因素分析
  • iPS细胞（诱导性多功能干细胞）市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析
    • COVID-19 影响分析

第四章 iPS细胞（诱导性多功能干细胞）市场：依细胞来源类型估算与趋势分析

  • 细分仪表板
  • 全球iPS细胞（诱导性多功能干细胞）市场：依来源细胞类型的波动分析
  • 2018-2030年全球iPS细胞（诱导性多功能干细胞）市场规模与趋势分析（依细胞来源类型）
  • 肝细胞
  • 纤维母细胞
  • 角质形成细胞
  • 羊膜细胞
  • 其他的

第五章 iPS细胞（诱导性多功能干细胞）市场：依应用估算与趋势分析

  • 细分仪表板
  • 全球iPS细胞（诱导性多功能干细胞）市场：应用变化分析
  • 2018-2030年全球iPS细胞（诱导性多功能干细胞）市场规模及趋势分析（依应用）
  • 药物开发
    • 2018-2030 年市场估计与预测
  • 组织工程与再生医学
    • 2018-2030 年市场估计与预测
    • 神经病学
    • 整形外科
    • 肿瘤学
    • 心血管疾病和心肌梗塞
    • 糖尿病
    • 其他的
  • 毒理学调查
    • 2018-2030 年市场估计与预测
  • 疾病模型
    • 2018-2030 年市场估计与预测

第六章 iPS 细胞（诱导性多功能干细胞）市场：以最终用途进行估算与趋势分析

  • 细分仪表板
  • 全球iPS细胞（诱导性多功能干细胞）市场：以最终用途分類的波动分析
  • 2018-2030年全球iPS细胞（诱导性多功能干细胞）市场规模与趋势分析（依最终用途）
  • 学术研究所
  • 製药和生物技术公司
  • 其他的

第七章 iPS细胞（诱导性多功能干细胞）市场：区域估计与趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 2018-2030 年北美市场估计与预测
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 2018-2030 年欧洲市场估计与预测
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 2018-2030 年亚太市场估计与预测
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 2018-2030 年拉丁美洲市场估计与预测
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 2018-2030 年中东和非洲市场估计和预测
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 公司/竞争对手分类
  • 策略规划
  • 2023 年企业市场分析
  • 公司简介/上市公司
    • STEMCELL Technologies Inc.
    • Cellular Engineering Technologies Inc.
    • REPROCELL Inc.
    • Takara Bio, Inc.
    • Axol Bioscience Ltd.
    • Fate Therapeutics, Inc.
    • FUJIFILM Cellular Dynamics, Inc.
    • Cynata Therapeutics Limited
    • Evotec SE
    • Astellas Pharma Inc.
Product Code: GVR-4-68040-116-1

Induced Pluripotent Stem Cells Market Growth & Trends:

The global induced pluripotent stem cells market size is expected to reach USD 3.31 billion by 2030, registering to grow at a CAGR of 10.21% from 2024 to 2030 according to a new report by Grand View Research, Inc. The market for induced pluripotent stem cells (iPSC) is expanding quickly. The ability of induced pluripotent stem cells to generate any cell or tissue essential by the body to fight or combat illnesses such as leukemia, spinal cord injury, cardiovascular disease, and diabetes is the primary reason for their utilization.

Other factors driving market expansion include higher research funding, an increase in the number of genomics initiatives, and a surge in the application of genome engineering in personalized drugs. This has accelerated the adoption of iPSC, resulting in the market's profitable revenue growth. For instance, in October 2020, Axxam S.p.A. & FUJIFILM Cellular Dynamics, Inc. announced a strategic partnership to advance the drug discovery process. Through the use of the most cutting-edge drug discovery techniques to enable target evaluation, High-Throughput Screening (HTS), & High-Content Screening, the partnership will give drug development researchers along with scientists access to an integrative platform of hiPSC-based assays.

Investments in healthcare development and research have expanded significantly in recent years, and this trend is projected to have a significant impact on induced pluripotent stem cell demand over the forecast period. The expanding spectrum of human iPSC cell lines' applications in precision medicine and the growing emphasis on stem cell therapeutic applications are predicted to be important factors driving induced pluripotent stem cell market expansion. For instance, in March 2021, Sana Biotechnology, Inc. received authorization to use FUJIFILM Cellular Dynamics' iPSC platform for the creation of commercially available cell therapies, according to a joint statement from both companies. Cell therapies can improve, fix, or substitute human biology, including cells, tissues, and organs.

The rise in research activity during the COVID-19 pandemic also enhanced iPSC-based research. In addition, scientists' ongoing efforts to discover novel therapies and treatments to manage the SARS CoV-2 infection have increased the need for iPSCs as research tools. Furthermore, induced pluripotent stem cells can create organoids or organ models that are physiologically equivalent, thus they can be utilized to study the pathophysiology of viral infection in humans. Thus, propelling the industry growth.

Furthermore, the government and commercial sectors are expanding funding along with growing industry that focuses on various scientific activities linked to iPSCs, and people are becoming more aware of stem cells through various organizations. However, challenges such as the high cost of cell reprograming, ethical concerns, and lengthy processes are inhibiting the growth of the induced pluripotent stem cell industry to a certain extend Moreover, low efficiency, potential tumor risk, and insufficient programming are other concerns restricting the expansion of the iPSC market.

Induced Pluripotent Stem Cells Market Report Highlights:

  • By derived cell type, the fibroblasts segment accounted for the largest share of 30.51% in 2023. The growing preference among healthcare professionals for fibroblast as potential treatments for skin problems are propelling the segment growth.
  • By application, the drug developmentsegment accounted for the largest share of 49.03% in 2023. The prevalence of chronic diseases, sedentary lifestyle, and others increase the demand for personalized therapies, and the increasing interest of pharma & biotech companies to develop drugs with the help of iPS cells promotes the industry growth.
  • By end-user, the pharmaceutical & biotechnology companies segment accounted for the largest share of 59.83% in 2023. This segment is projected to dominate the market since they make and develop various stem cell products & technology for various diseases employing induced pluripotent stem cells.
  • North America held the larger share of 36.11% in 2023. This is mostly due to increased use of innovative systems and technologies in drug research, toxicity testing, and disease modeling, as well as the region's growing acceptance of stem cell therapies are the major reasons for driving the market.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Derived Cell Type Segment
    • 1.2.2. Application Segment
    • 1.2.3. End Use Segment
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Induced Pluripotent Stem Cells Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of chronic diseases
      • 3.2.1.2. Increasing research and development activities in stem cell therapies
      • 3.2.1.3. Growing adoption of personalized medicine
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of treatment
  • 3.3. Induced Pluripotent Stem Cells Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Induced Pluripotent Stem Cells Market: Derived Cell Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Induced Pluripotent Stem Cells Market Derived Cell Type Movement Analysis
  • 4.3. Global Induced Pluripotent Stem Cells Market Size & Trend Analysis, by Derived Cell Type, 2018 to 2030 (USD Million)
  • 4.4. Hepatocytes
    • 4.4.1. Hepatocytes market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.5. Fibroblasts
    • 4.5.1. Fibroblasts market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.6. Keratinocytes
    • 4.6.1. Keratinocytes market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.7. Amniotic Cells
    • 4.7.1. Amniotic cells market estimates and forecasts 2018 - 2030 (USD Million)
  • 4.8. Others
    • 4.8.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 5. Induced Pluripotent Stem Cells Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Induced Pluripotent Stem Cells Market Application Movement Analysis
  • 5.3. Global Induced Pluripotent Stem Cells Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Drug Development
    • 5.4.1. Drug development market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.5. Tissue Engineering & Regenerative Medicine
    • 5.5.1. Tissue engineering & regenerative medicine market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.2. Neurology
      • 5.5.2.1. Neurology market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.3. Orthopedics
      • 5.5.3.1. Orthopedics market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.4. Oncology
      • 5.5.4.1. Oncology market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.5. Cardiovascular & Myocardial Infarction
      • 5.5.5.1. Cardiovascular & myocardial infarction market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.6. Diabetes
      • 5.5.6.1. Diabetes market estimates and forecasts 2018 - 2030 (USD Million)
    • 5.5.7. Others
      • 5.5.7.1. Others market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.6. Toxicology Research
    • 5.6.1. Toxicology research market estimates and forecasts 2018 - 2030 (USD Million)
  • 5.7. Disease Modeling
    • 5.7.1. Disease modeling market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 6. Induced Pluripotent Stem Cells Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Global Induced Pluripotent Stem Cells Market End Use Movement Analysis
  • 6.3. Global Induced Pluripotent Stem Cells Market Size & Trend Analysis, by End use, 2018 to 2030 (USD Million)
  • 6.4. Academic & Research Institutes
    • 6.4.1. Academic & research institutes market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.5. Pharmaceutical & Biotechnology Companies
    • 6.5.1. Pharmaceutical & biotechnology companies market estimates and forecasts 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 7. Induced Pluripotent Stem Cells Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Competitive scenario
      • 7.4.2.3. Regulatory framework
      • 7.4.2.4. Target disease prevalence
      • 7.4.2.5. U.S. market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Competitive scenario
      • 7.4.3.3. Regulatory framework
      • 7.4.3.4. Target disease prevalence
      • 7.4.3.5. Canada market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Competitive scenario
      • 7.4.4.3. Regulatory framework
      • 7.4.4.4. Target disease prevalence
      • 7.4.4.5. Mexico market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Competitive scenario
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Target disease prevalence
      • 7.5.2.5. UK market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Competitive scenario
      • 7.5.3.3. Regulatory framework
      • 7.5.3.4. Target disease prevalence
      • 7.5.3.5. Germany market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Competitive scenario
      • 7.5.4.3. Regulatory framework
      • 7.5.4.4. Target disease prevalence
      • 7.5.4.5. France market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Competitive scenario
      • 7.5.5.3. Regulatory framework
      • 7.5.5.4. Target disease prevalence
      • 7.5.5.5. Italy market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Competitive scenario
      • 7.5.6.3. Regulatory framework
      • 7.5.6.4. Target disease prevalence
      • 7.5.6.5. Spain market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key country dynamics
      • 7.5.7.2. Competitive scenario
      • 7.5.7.3. Regulatory framework
      • 7.5.7.4. Target disease prevalence
      • 7.5.7.5. Denmark market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key country dynamics
      • 7.5.8.2. Competitive scenario
      • 7.5.8.3. Regulatory framework
      • 7.5.8.4. Target disease prevalence
      • 7.5.8.5. Sweden market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key country dynamics
      • 7.5.9.2. Competitive scenario
      • 7.5.9.3. Regulatory framework
      • 7.5.9.4. Target disease prevalence
      • 7.5.9.5. Norway market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Competitive scenario
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Target disease prevalence
      • 7.6.2.5. Japan market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Competitive scenario
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Target disease prevalence
      • 7.6.3.5. China market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Competitive scenario
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Target disease prevalence
      • 7.6.4.5. India market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Competitive scenario
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Target disease prevalence
      • 7.6.5.5. South Korea market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Competitive scenario
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Target disease prevalence
      • 7.6.6.5. Australia market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Competitive scenario
      • 7.6.7.3. Regulatory framework
      • 7.6.7.4. Target disease prevalence
      • 7.6.7.5. Thailand market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Competitive scenario
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Target disease prevalence
      • 7.7.2.5. Brazil market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Competitive scenario
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Target disease prevalence
      • 7.7.3.5. Argentina market estimates and forecasts 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Competitive scenario
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Target disease prevalence
      • 7.8.2.5. South Africa market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Competitive scenario
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. Target disease prevalence
      • 7.8.3.5. Saudi Arabia market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Competitive scenario
      • 7.8.4.3. Regulatory framework
      • 7.8.4.4. Target disease prevalence
      • 7.8.4.5. UAE market estimates and forecasts 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key country dynamics
      • 7.8.5.2. Competitive scenario
      • 7.8.5.3. Regulatory framework
      • 7.8.5.4. Target disease prevalence
      • 7.8.5.5. Kuwait market estimates and forecasts 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Strategy Mapping
  • 8.3. Company Market Position Analysis, 2023
  • 8.4. Company Profiles/Listing
    • 8.4.1. STEMCELL Technologies Inc.
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Cellular Engineering Technologies Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. REPROCELL Inc.
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. Takara Bio, Inc.
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Axol Bioscience Ltd.
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Fate Therapeutics, Inc.
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. FUJIFILM Cellular Dynamics, Inc.
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Cynata Therapeutics Limited
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Evotec SE
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Astellas Pharma Inc.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 Global induced pluripotent stem cells market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 4 Global induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 5 Global induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 6 North America induced pluripotent stem cells market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 8 North America induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 9 North America induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 10 U.S. induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 11 U.S. induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 12 U.S. induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 13 Canada induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 14 Canada induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 15 Canada induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 16 Mexico induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 17 Mexico induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 18 Mexico induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 19 Europe induced pluripotent stem cells market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 21 Europe induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 22 Europe induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 23 Germany induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 24 Germany induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 25 Germany induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 26 UK induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 27 UK induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 28 UK induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 29 France induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 30 France induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 31 France induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 32 Italy induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 33 Italy induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 34 Italy induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 35 Spain induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 36 Spain induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 37 Spain induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 38 Denmark induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 39 Denmark induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 40 Denmark induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 41 Sweden induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 42 Sweden induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 43 Sweden induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 44 Norway induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 45 Norway induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 46 Norway induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 47 Asia Pacific induced pluripotent stem cells market, by country, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 51 China induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 52 China induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 53 China induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 54 Japan induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 55 Japan induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 56 Japan induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 57 India induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 58 India induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 59 India induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 60 South Korea induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 61 South Korea induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 62 South Korea induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 63 Australia induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 64 Australia induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 65 Australia induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 66 Thailand induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 67 Thailand induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 68 Thailand induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 69 Latin America induced pluripotent stem cells market, by country, 2018 - 2030 (USD Million)
  • Table 70 Latin America induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 71 Latin America induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 72 Latin America induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 73 Brazil induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 74 Brazil induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 75 Brazil induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 76 Argentina induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 77 Argentina induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 78 Argentina induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 79 MEA induced pluripotent stem cells market, by country, 2018 - 2030 (USD Million)
  • Table 80 MEA induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 81 MEA induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 82 MEA induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 83 South Africa induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 84 South Africa induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 85 South Africa induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 89 UAE induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 90 UAE induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 91 UAE induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)
  • Table 92 Kuwait induced pluripotent stem cells market, by derived cell type, 2018 - 2030 (USD Million)
  • Table 93 Kuwait induced pluripotent stem cells market, by application, 2018 - 2030 (USD Million)
  • Table 94 Kuwait induced pluripotent stem cells market, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market formulation & validation
  • Fig. 4 Induced pluripotent stem cells market: Market outlook
  • Fig. 5 Induced pluripotent stem cells market: Segment outlook
  • Fig. 6 Induced pluripotent stem cells market: Competitive landscape outlook
  • Fig. 7 Parent market outlook
  • Fig. 8 Induced pluripotent stem cells market driver impact
  • Fig. 9 Induced pluripotent stem cells market restraint impact
  • Fig. 10 Induced pluripotent stem cells market: Type outlook and key takeaways
  • Fig. 11 Induced pluripotent stem cells market: Type movement analysis
  • Fig. 12 Hepatocytes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 13 Fibroblasts market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 14 Keratinocytes market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 Amniotic cells market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Induced pluripotent stem cells market: Application outlook and key takeaways
  • Fig. 18 Induced pluripotent stem cells market: Application movement analysis
  • Fig. 19 Drug development market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Tissue engineering & regenerative medicine market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Neurology market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 22 Orthopedics market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 23 Oncology market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 24 Cardiovascular and myocardial infarction market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 25 Diabetes market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 26 Others market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 27 Toxicology research market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 28 Disease modeling market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 29 Induced pluripotent stem cells market: End use outlook and key takeaways
  • Fig. 30 Induced pluripotent stem cells market: End use movement analysis
  • Fig. 31 Academic & research institutes market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 Pharmaceutical & biotechnology companies market estimates and forecasts,2018 - 2030 (USD Million)
  • Fig. 33 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Global induced pluripotent stem cells market: Regional outlook and key takeaways
  • Fig. 35 Global induced pluripotent stem cells market: Regional movement analysis
  • Fig. 36 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 37 Key country dynamics
  • Fig. 38 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 Key country dynamics
  • Fig. 40 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Key country dynamics
  • Fig. 42 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 44 Key country dynamics
  • Fig. 45 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 46 Key country dynamics
  • Fig. 47 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 48 Key country dynamics
  • Fig. 49 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 50 Key country dynamics
  • Fig. 51 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 52 Key country dynamics
  • Fig. 53 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Key country dynamics
  • Fig. 55 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 Key country dynamics
  • Fig. 57 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 63 Key country dynamics
  • Fig. 64 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 65 Key country dynamics
  • Fig. 66 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Key country dynamics
  • Fig. 70 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Key country dynamics
  • Fig. 72 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 Key country dynamics
  • Fig. 75 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 Key country dynamics
  • Fig. 82 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Key country dynamics
  • Fig. 84 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Key country dynamics
  • Fig. 86 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)